{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:24:10Z","timestamp":1789118650847,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Curtin University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Polypharmacy is often associated with adverse clinical outcomes and increased medication management complexity. However conventional analyses of medicine burden and polypharmacy using administrative data are limited to oral medicines (i.e. tablets and capsules), potentially underestimating overall medicine exposure. These products may significantly increase the burden of medication management and therefore risk to patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study compared traditional measures of polypharmacy with a measure incorporating all modes of medicine administration and examined how these differences impacted estimates of polypharmacy prevalence among adults aged\u2009&gt;\u200965\u00a0years in Western Australia (WA) from 2012\/13 to 2018\/19, between two independent cohorts: community-dwelling and residential aged care home populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Linked medication dispensing data were used to classify and compare medicines between community-dwelling and residential aged care populations in Western Australia. Conventional medicine capture was extended to include medicines via various modes of administration, including creams, ointments, patches, and eye and ear drops. Medicines were classified into five categories: 0, 1, 2\u20134, 5\u20138, 9\u2009+\u2009medicines, and counts were compared across care settings to assess changes in observed medicine burden and measures of polypharmacy. Comparative analysis was performed between two methods: Method 1 (conventional medicine capture) and Method 2 (all medicines including non-oral preparations).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inclusion of medicines via mode of administration increased observed medicine burden in both subpopulations, with a greater relative increase in residential aged care. This approach notably contributed to total medicine counts, revealing previously unrecognised medicine exposure. This resulted in absolute increases in the 5\u2009+\u2009medicine category of 4.0% in 2012\/13 and 3.4% in 2018\/19. Among aged care residents, opioid analgesics previously ranked as the most common medicine class using Method 1, was reclassified as separate oral and patch formulations using Method 2, ranking 4th and 5th. Drugs for dry eyes also emerged as the 7th most common medicine class, with only minor ranking changes observed for the other top medicine classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Incorporating all modes of medicine administration into a polypharmacy measure substantially altered estimates of medicine burden and identified previously unrecognised exposure, particularly among residential aged care populations. The impact was greatest in higher polypharmacy categories, indicating that conventional approaches may underestimate medicine use in individuals with more complex therapeutic regimens. These findings highlight the importance of accounting for formulation diversity and support the inclusion of mode-of-administration\u2013based measures to provide a more comprehensive assessment of medication exposure and complexity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02194-0","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:47:51Z","timestamp":1785476871000},"page":"2158-2168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of existing polypharmacy measures to a measure incorporating all modes of administration: an observational study using routinely collected data"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-4320","authenticated-orcid":false,"given":"David","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4296-4161","authenticated-orcid":false,"given":"David","family":"Youens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-7151","authenticated-orcid":false,"given":"Rachael","family":"Moorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-6846","authenticated-orcid":false,"given":"Andrew","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2194_CR1","unstructured":"Wilmoth JR, Bas D, Mukherjee S, et al. World social report 2023: Leaving no one behind in an ageing world: UN; 2023. ISBN:9210019687."},{"issue":"3","key":"2194_CR2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s11096-025-01882-7","volume":"47","author":"GB Lee","year":"2025","unstructured":"Lee GB, Hosking SM, Etherton-Beer C, et al. Defining polypharmacy in older adults: a cross-sectional comparison of prevalence estimates calculated according to active ingredient and unique product counts. Int J Clin Pharm. 2025;47(3):824\u201333. https:\/\/doi.org\/10.1007\/s11096-025-01882-7.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2194_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5694\/mja2.50244","volume":"211","author":"AT Page","year":"2006","unstructured":"Page AT, Falster MO, Litchfield M, et al. Polypharmacy among older Australians, 2006\u20132017: a population\u2010based study. Med J Aust. 2006;211(2):71\u20135. https:\/\/doi.org\/10.5694\/mja2.50244.","journal-title":"Med J Aust"},{"issue":"6","key":"2194_CR4","doi-asserted-by":"publisher","first-page":"535.e1","DOI":"10.1016\/j.jamda.2015.03.003","volume":"16","author":"N Jokanovic","year":"2015","unstructured":"Jokanovic N, Tan EC, Dooley MJ, et al. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16(6):535.e1-12. https:\/\/doi.org\/10.1016\/j.jamda.2015.03.003.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"2194_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","volume":"12","author":"F Pazan","year":"2021","unstructured":"Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443\u201352. https:\/\/doi.org\/10.1007\/s41999-021-00479-3.","journal-title":"Eur Geriatr Med"},{"issue":"12","key":"2194_CR6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/bmjqs-2023-017042","volume":"33","author":"N Wabe","year":"2024","unstructured":"Wabe N, Urwin R, Seaman K, et al. Longitudinal cohort study of discrepancies between prescribed and administered polypharmacy rates: implications for National Aged Care Quality Indicator Programs. BMJ Qual Saf. 2024;33(12):780\u20139. https:\/\/doi.org\/10.1136\/bmjqs-2023-017042.","journal-title":"BMJ Qual Saf"},{"issue":"1","key":"2194_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https:\/\/doi.org\/10.1186\/s12877-017-0621-2.","journal-title":"BMC Geriatr"},{"issue":"2","key":"2194_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40266-025-01274-6","volume":"43","author":"GB Lee","year":"2013","unstructured":"Lee GB, Etherton-Beer C, Pasco JA, et al. Australian polypharmacy trends between 2013 and 2024: a repeated cross-sectional study in the adult population. Drugs Aging. 2013;43(2):163\u201374. https:\/\/doi.org\/10.1007\/s40266-025-01274-6.","journal-title":"Drugs Aging"},{"issue":"6","key":"2194_CR9","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s40123-023-00831-9","volume":"12","author":"NM Radcliffe","year":"2023","unstructured":"Radcliffe NM, Shah M, Samuelson TW. Challenging the \u201ctopical medications-first\u201d approach to glaucoma: a treatment paradigm in evolution. Ophthalmol Ther. 2023;12(6):2823\u201339. https:\/\/doi.org\/10.1007\/s40123-023-00831-9.","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"2194_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ogla.2025.04.001","volume":"8","author":"T Wang","year":"2025","unstructured":"Wang T, An HS, Stoutin J, et al. Association of eye drop\u2013treated diseases and conditions that can impair eye drop self-administration. Ophthalmol Glaucoma. 2025;8(5):431\u20139. https:\/\/doi.org\/10.1016\/j.ogla.2025.04.001.","journal-title":"Ophthalmol Glaucoma"},{"issue":"8","key":"2194_CR11","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41433-019-0665-y","volume":"34","author":"E Mehuys","year":"2020","unstructured":"Mehuys E, Delaey C, Christiaens T, et al. Eye drop technique and patient-reported problems in a real-world population of eye drop users. Eye (Lond). 2020;34(8):1392\u20138. https:\/\/doi.org\/10.1038\/s41433-019-0665-y.","journal-title":"Eye (Lond)"},{"issue":"1","key":"2194_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-01568-x","volume":"20","author":"I Maidment","year":"2020","unstructured":"Maidment I, Lawson S, Wong G, et al. Towards an understanding of the burdens of medication management affecting older people: the MEMORABLE realist synthesis. BMC Geriatr. 2020;20(1):183. https:\/\/doi.org\/10.1186\/s12877-020-01568-x.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2194_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04444-6","volume":"23","author":"C Yang","year":"2023","unstructured":"Yang C, Zhu S, Hui Z, et al. Psychosocial factors associated with medication burden among community-dwelling older people with multimorbidity. BMC Geriatr. 2023;23(1):741. https:\/\/doi.org\/10.1186\/s12877-023-04444-6.","journal-title":"BMC Geriatr"},{"issue":"9","key":"2194_CR14","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1345\/aph.1d479","volume":"38","author":"J George","year":"2004","unstructured":"George J, Phun Y-T, Bailey MJ, et al. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369\u201376. https:\/\/doi.org\/10.1345\/aph.1d479.","journal-title":"Ann Pharmacother"},{"key":"2194_CR15","unstructured":"Australian Medicines H, Buckley N. AMH Australian medicines handbook 2020. Adelaide, South Australia: Australian Medicines Handbook; 2020. ISBN:9780648515814."},{"key":"2194_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"1995","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 1995;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med"},{"key":"2194_CR17","unstructured":"Australian Institute of Health and Welfare (AIHW) - GEN AGED CARE DATA. People's care needs in aged care: Care needs in permanent residential care Canberra, Australia: AIHW, Australian Government; 2026. Available from: https:\/\/www.gen-agedcaredata.gov.au\/topics\/people-s-care-needs-in-aged-care#careneedsinpermanentresidentialcare. Accessed 13 May 2026."},{"key":"2194_CR18","unstructured":"Australian Institute of Health and Welfare (AIHW). Aged care Canberra, Australia: AIHW, Australian Government; 2025. Available from: https:\/\/www.aihw.gov.au\/reports\/australias-welfare\/aged-care. Accessed 13 May 2026."},{"key":"2194_CR19","unstructured":"Australian Institute of Health and Welfare (AIHW). Factsheet 2018\u201319: People's care needs in permanent residential aged care Canberra, Australia: GEN Aged Care Data, Australian Institute of Health and Welfare; 2019. Available from: https:\/\/www.gen-agedcaredata.gov.au\/getmedia\/96f4e42c-3e3d-4994-87ef-368b3e2a9724\/Peoples-care-needs-in-aged-care-factsheet.pdf. Accessed 30 June 2026."},{"issue":"Suppl 2","key":"2194_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.12445","volume":"28","author":"I Zschocke","year":"2014","unstructured":"Zschocke I, Mrowietz U, Karakasili E, et al. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):4\u20139. https:\/\/doi.org\/10.1111\/jdv.12445.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2194_CR21","unstructured":"Australian Government Department of Health and Aged Care. National Aged Care Mandatory Quality Indicator Program (QI Program) - About the QI Program Canberra, Australia: Commonwealth of Australia; 2023. Available from: https:\/\/www.health.gov.au\/our-work\/qi-program\/about. Accessed 19 APR 2025."},{"issue":"4","key":"2194_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf102","volume":"54","author":"H Al Shaker","year":"2025","unstructured":"Al Shaker H, Barry H, Hughes C. Development of a core outcome set for clinical trials targeting interventions aiming to improve adherence to appropriate polypharmacy in older people\u2014an international consensus study. Age Ageing. 2025; 54(4), afaf102. https:\/\/doi.org\/10.1093\/ageing\/afaf102.","journal-title":"Age Ageing"},{"issue":"9","key":"2194_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd008165.pub4","volume":"9","author":"A Rankin","year":"2018","unstructured":"Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9(9):Cd008165. https:\/\/doi.org\/10.1002\/14651858.cd008165.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2194_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1078-7","volume":"16","author":"J Burt","year":"2018","unstructured":"Burt J, Elmore N, Campbell SM, et al. Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med. 2018;16(1):91. https:\/\/doi.org\/10.1186\/s12916-018-1078-7.","journal-title":"BMC Med"},{"issue":"5","key":"2194_CR25","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1016\/S2666-7568(21)00054-4","volume":"2","author":"PA Rochon","year":"2021","unstructured":"Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Healthy Longev. 2021;2(5):e290\u2013300. https:\/\/doi.org\/10.1016\/S2666-7568(21)00054-4.","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"2194_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.18773\/austprescr.2025.030","volume":"48","author":"A Choo","year":"2025","unstructured":"Choo A. Potentially inappropriate medicines for older people: consensus-based lists. Aust Prescr. 2025;48(4):128.","journal-title":"Aust Prescr"},{"issue":"1","key":"2194_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82285-y","volume":"14","author":"N Tantipinichwong","year":"2024","unstructured":"Tantipinichwong N, Keller MS. Operation polypharmacy: a pharmacist-led ambulatory care clinic design and evaluation for older patients. Sci Rep. 2024;14(1):31719. https:\/\/doi.org\/10.1038\/s41598-024-82285-y.","journal-title":"Sci Rep"},{"key":"2194_CR28","unstructured":"World Health Organiztion (WHO) Collaborating Centre for Drug Statistics Methodology. ATC\/DDD index: WHO Collaborating Centre for Drug Statistics; 2026. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/. Accessed 20 Jan 2026."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02194-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02194-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02194-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:32Z","timestamp":1789117112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02194-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02194-0","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was obtained from Curtin University (Approval No. RD-42\u201314), the Department of Health Western Australia (Approval No. RGS0000002902), and the Australian Institute of Health and Welfare (Approval No. EO2020\/2\/1138 ID 2533) under a waiver of consent.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}